QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)

Arvinas (ARVN) Stock Forecast, Price & News

$19.79
-0.61 (-2.99%)
(As of 09/28/2023 ET)
Compare
Today's Range
$19.57
$20.72
50-Day Range
$20.40
$28.21
52-Week Range
$19.57
$57.96
Volume
401,256 shs
Average Volume
445,350 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.07

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
223.8% Upside
$64.07 Price Target
Short Interest
Bearish
6.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.85mentions of Arvinas in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$32,292 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.14) to ($7.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

356th out of 969 stocks

Pharmaceutical Preparations Industry

150th out of 455 stocks


ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Price History

ARVN Stock News Headlines

Arvinas' Potential In Treating ER+, HER2- Breast Cancer
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
7 Analysts Have This to Say About Arvinas
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
What 8 Analyst Ratings Have To Say About Arvinas
Arvinas: Nothing Interesting In The Near Term
6 Analysts Have This to Say About Arvinas
Where Arvinas Stands With Analysts
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
415
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.07
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+219.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-191.63%
Pretax Margin
-178.43%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$10.61 per share

Miscellaneous

Free Float
52,121,000
Market Cap
$1.07 billion
Optionable
Not Optionable
Beta
1.72
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 63)
    Chairperson, CEO & Pres
    Comp: $1.08M
  • Mr. Sean A. Cassidy CPAMr. Sean A. Cassidy CPA (Age 53)
    CPA, M.B.A., CFO, Principal Financial Officer & Treasurer
    Comp: $683k
  • Dr. Ian Taylor Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Ronald A. Peck M.D. (Age 57)
    Chief Medical Officer
    Comp: $701.63k
  • Mr. David K. Loomis M.B.A. (Age 49)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    VP of Investor Relations
  • Dr. Randy Teel Ph.D. (Age 44)
    Sr. VP of Corp. & Bus. Devel.
  • Mr. Steve Weiss (Age 53)
    Sr. VP & Chief HR Officer
  • Dr. John A. Grosso Ph.D. (Age 66)
    Sr. VP of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 55)
    Sr. VP of Neuroscience & Platform Biology













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

15 analysts have issued 12 month price objectives for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they predict the company's share price to reach $64.07 in the next twelve months. This suggests a possible upside of 219.2% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the start of the year. Since then, ARVN shares have decreased by 41.3% and is now trading at $20.07.
View the best growth stocks for 2023 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.40. The firm earned $54.50 million during the quarter, compared to analysts' expectations of $30.94 million. Arvinas had a negative net margin of 191.63% and a negative trailing twelve-month return on equity of 55.09%. Arvinas's revenue was up 74.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.32) EPS.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.17%), JPMorgan Chase & Co. (3.74%), ArrowMark Colorado Holdings LLC (3.37%), State Street Corp (2.09%), Geode Capital Management LLC (1.86%) and Candriam S.C.A. (0.88%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $20.07.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.07 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 415 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -